Transferrin-conjugated doxorubicin-loaded lipid-coated nanoparticles for the targeting and therapy of lung cancer

Guo,Yajun; Wang,Lijuan; Lv,Peng; Zhang,Peng

doi:10.3892/ol.2014.2840

Transferrin-conjugated doxorubicin-loaded lipid-coated nanoparticles for the targeting and therapy of lung cancer

Authors:
- Yajun Guo
- Lijuan Wang
- Peng Lv
- Peng Zhang
View Affiliations

Affiliations: Department of Nursing, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China, Department of Cardiothoracic Surgery, Tianjin Medical University General Hospital, Heping, Tianjin 300052, P.R. China
Published online on: December 30, 2014 https://doi.org/10.3892/ol.2014.2840
Pages: 1065-1072
Copyright: © Guo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In the present study, a targetable vector was developed for the targeted delivery of anticancer agents, consisting of lipid‑coated poly D,L‑lactic‑co‑glycolic acid nanoparticles (PLGA‑NP) that were modified with transferrin (TF). Doxorubicin (DOX) was used as a model drug for lung cancer therapy. The use of these NPs combined the advantages and avoided the disadvantages exhibited individually by liposomes and polymeric NPs during drug delivery. The lipid coating of the polymeric core was confirmed by transmission electron microscopy. The physicochemical characteristics of transferrin‑conjugated lipid‑coated NPs (TF‑LP), including the particle size, zeta potential, morphology, encapsulation efficiency and in vitro DOX release, were also evaluated. The cellular uptake investigation in the present study found that TF‑LP was more efficiently endocytosed by the A549 cells, than LP and PLGA‑NPs. Furthermore, the anti‑proliferative effect exhibited by DOX‑loaded TF‑LPs on A549 cells and the inhibition of tumor spheroid growth was stronger compared with the effect of DOX‑loaded lipid‑coated PLGA‑NPs and PLGA‑NPs. In the in vivo component of the present study, TF‑LP demonstrated the best inhibitory effect on tumor growth in the A549 tumor‑bearing mice. It was concluded that TF‑LP may be an efficient targeted drug‑delivery system for lung cancer therapy.

View Figures

View References

1	Jinturkar KA, Anish C, Kumar MK, et al: Liposomal formulations of Etoposide and Docetaxel for p53 mediated enhanced cytotoxicity in lung cancer cell lines. Biomaterials. 33:2492–2507. 2012. View Article : Google Scholar
2	Sengupta S, Tyagi P, Velpandian T, et al: Etoposide encapsulated in positively charged liposomes: pharmacokinetic studies in mice and formulation stability studies. Pharmacol Res. 42:459–464. 2000. View Article : Google Scholar : PubMed/NCBI
3	Li R, Zhang Q, Wang XY, et al: A targeting drug delivery system for ovarian carcinoma: transferring modified lipid coated paclitaxel-loaded nanoparticles. Drug Res (Stuttg). 64:541–547. 2014. View Article : Google Scholar
4	Oh S, Kim BJ, Singh NP, et al: Synthesis and anti-cancer activity of covalent conjugates of artemisinin and a transferrin-receptor targeting peptide. Cancer Lett. 274:33–39. 2009. View Article : Google Scholar
5	Hu CM and Zhang L: Therapeutic nanoparticles to combat cancer drug resistance. Curr Drug Metab. 10:836–841. 2009. View Article : Google Scholar
6	Torchilin VP: Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 4:145–160. 2005. View Article : Google Scholar : PubMed/NCBI
7	Wang AZ, Bagalkot V, Vasilliou CC, et al: Superparamagnetic iron oxide nanoparticle-aptamer bioconjugates for combined prostate cancer imaging and therapy. ChemMedChem. 3:1311–1315. 2008. View Article : Google Scholar : PubMed/NCBI
8	Nakatsuji T, Kao MC, Zhang L, et al: Sebum free fatty acids enhance the innate immune defense of human sebocytes by upregulating beta-defensin-2 expression. J Invest Dermatol. 130:985–994. 2010. View Article : Google Scholar
9	Hu CM, Kaushal S, Tran Cao HS, et al: Half-antibody functionalized lipid-polymer hybrid nanoparticles for targeted drug delivery to carcinoembryonic antigen presenting pancreatic cancer cells. Mol Pharm. 7:914–920. 2010. View Article : Google Scholar : PubMed/NCBI
10	Kibria G, Hatakeyama H, Ohga N, et al: Dual-ligand modification of PEGylated liposomes shows better cell selectivity and efficient gene delivery. J Control Release. 153:141–148. 2011. View Article : Google Scholar : PubMed/NCBI
11	Sharma G, Modgil A, Sun C and Singh J: Grafting of cell-penetrating peptide to receptor-targeted liposomes improves their transfection efficiency and transport across blood-brain barrier model. J Pharm Sci. 101:2468–2478. 2012. View Article : Google Scholar : PubMed/NCBI
12	Wadia JS and Dowdy SF: Protein transduction technology. Curr Opin Biotechnol. 13:52–56. 2002. View Article : Google Scholar : PubMed/NCBI
13	Wang H, Zhao Y, Wu Y, et al: Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles. Biomaterials. 32:8281–8290. 2011. View Article : Google Scholar : PubMed/NCBI
14	Cui Y, Xu Q, Chow PK, et al: Transferrin-conjugated magnetic silica PLGA nanoparticles loaded with doxorubicin and paclitaxel for brain glioma treatment. Biomaterials. 34:8511–8520. 2013. View Article : Google Scholar : PubMed/NCBI
15	Chan JM, Zhang L, Yuet KP, et al: PLGA-lecithin-PEG core-shell nanoparticles for controlled drug delivery. Biomaterials. 30:1627–1634. 2009. View Article : Google Scholar
16	Zhang L, Chan JM, Gu FX, et al: Self-assembled lipid-polymer hybrid nanoparticles: a robust drug delivery platform. ACS Nano. 2:1696–1702. 2008. View Article : Google Scholar
17	Yang X, Koh CG, Liu S, et al: Transferrin receptor-targeted lipid nanoparticles for delivery of an antisense oligodeoxyribonucleotide against Bcl-2. Mol Pharm. 6:221–230. 2009. View Article : Google Scholar : PubMed/NCBI
18	Chiu SJ, Liu S, Perrotti D, et al: Efficient delivery of a Bcl-2-specific antisense oligodeoxyribonucleotide (G3139) via transferrin receptor-targeted liposomes. J Controlled Release. 112:199–207. 2006. View Article : Google Scholar
19	Jiang T, Zhang Z, Zhang Y, et al: Dual-functional liposomes based on pH-responsive cell-penetrating peptide and hyaluronic acid for tumor-targeted anticancer drug delivery. Biomaterials. 33:9246–9258. 2012. View Article : Google Scholar : PubMed/NCBI
20	Maeda N, Takeuchi Y, Takada M, et al: Anti-neovascular therapy by use of tumor neovasculature-targeted long-circulating liposome. J Control Release. 100:41–52. 2004. View Article : Google Scholar : PubMed/NCBI
21	Lewis CE and Pollard JW: Distinct role of macrophages in different tumor microenvironments. Cancer Res. 66:605–612. 2006. View Article : Google Scholar : PubMed/NCBI
22	Fukumura D, Xu L, Chen Y, Gohongi T, et al: Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo. Cancer Res. 61:6020–6024. 2001.PubMed/NCBI
23	Jain RK: Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev. 64(Suppl): 353–365. 2012. View Article : Google Scholar : PubMed/NCBI
24	Wang X, Yang L, Chen ZG and Shin DM: Application of nanotechnology in cancer therapy and imaging. CA Cancer J Clin. 58:97–110. 2008. View Article : Google Scholar : PubMed/NCBI
25	Chen X, Wang X, Wang Y, et al: Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide. J Control Release. 145:17–25. 2010. View Article : Google Scholar : PubMed/NCBI